Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2025 | 369 | 4.570 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 6 | 2023 | 35 | 4.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 7 | 2026 | 54 | 2.800 |
Why?
|
| Prostatic Neoplasms | 16 | 2022 | 493 | 2.550 |
Why?
|
| Electronic Health Records | 7 | 2026 | 393 | 1.590 |
Why?
|
| Algorithms | 3 | 2026 | 1050 | 1.180 |
Why?
|
| SEER Program | 6 | 2025 | 75 | 1.150 |
Why?
|
| Lymphoma, Follicular | 2 | 2026 | 18 | 1.140 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 524 | 1.130 |
Why?
|
| Multimorbidity | 3 | 2025 | 50 | 1.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2026 | 67 | 1.110 |
Why?
|
| Aged | 40 | 2026 | 14965 | 1.030 |
Why?
|
| Early Detection of Cancer | 6 | 2024 | 325 | 0.990 |
Why?
|
| Diet | 5 | 2021 | 536 | 0.860 |
Why?
|
| United States | 27 | 2026 | 8093 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2026 | 373 | 0.810 |
Why?
|
| Middle Aged | 37 | 2026 | 18273 | 0.810 |
Why?
|
| Aged, 80 and over | 20 | 2025 | 5614 | 0.790 |
Why?
|
| Male | 43 | 2026 | 31047 | 0.770 |
Why?
|
| Registries | 6 | 2026 | 924 | 0.760 |
Why?
|
| Healthcare Disparities | 3 | 2026 | 407 | 0.760 |
Why?
|
| Humans | 63 | 2026 | 65140 | 0.740 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 74 | 0.730 |
Why?
|
| Paraproteinemias | 1 | 2022 | 16 | 0.720 |
Why?
|
| Breast Neoplasms | 5 | 2025 | 1222 | 0.710 |
Why?
|
| Prostate-Specific Antigen | 3 | 2022 | 84 | 0.690 |
Why?
|
| Colorectal Neoplasms | 3 | 2023 | 286 | 0.690 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 136 | 0.640 |
Why?
|
| Cause of Death | 3 | 2020 | 221 | 0.630 |
Why?
|
| Case-Control Studies | 12 | 2022 | 1141 | 0.620 |
Why?
|
| Adult | 27 | 2026 | 17358 | 0.580 |
Why?
|
| Disease Progression | 6 | 2023 | 1220 | 0.570 |
Why?
|
| Comorbidity | 6 | 2025 | 1119 | 0.550 |
Why?
|
| Female | 29 | 2026 | 34018 | 0.540 |
Why?
|
| Hypertension | 1 | 2023 | 612 | 0.520 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 285 | 0.490 |
Why?
|
| Fatty Acids | 2 | 2018 | 198 | 0.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 214 | 0.450 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 54 | 0.440 |
Why?
|
| Risk Factors | 14 | 2022 | 5429 | 0.440 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 801 | 0.400 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 17 | 0.400 |
Why?
|
| Population Health | 2 | 2023 | 17 | 0.380 |
Why?
|
| Dietary Fats | 2 | 2017 | 180 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 863 | 0.370 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2024 | 5 | 0.360 |
Why?
|
| Young Adult | 10 | 2026 | 4809 | 0.350 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 121 | 0.350 |
Why?
|
| Prospective Studies | 11 | 2020 | 3308 | 0.340 |
Why?
|
| Vitamin D | 1 | 2012 | 139 | 0.330 |
Why?
|
| Zinc | 1 | 2011 | 95 | 0.310 |
Why?
|
| Medicare | 2 | 2025 | 625 | 0.310 |
Why?
|
| Sweden | 4 | 2017 | 65 | 0.300 |
Why?
|
| Cytokines | 1 | 2013 | 952 | 0.300 |
Why?
|
| Neoplasm Staging | 7 | 2026 | 544 | 0.290 |
Why?
|
| Tooth Loss | 2 | 2008 | 8 | 0.280 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2022 | 41 | 0.270 |
Why?
|
| Mammography | 2 | 2022 | 290 | 0.270 |
Why?
|
| Databases, Factual | 4 | 2025 | 883 | 0.270 |
Why?
|
| Neoplasms | 4 | 2019 | 1368 | 0.260 |
Why?
|
| Mortality | 3 | 2019 | 161 | 0.260 |
Why?
|
| Time-to-Treatment | 2 | 2026 | 133 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2014 | 509 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 2483 | 0.250 |
Why?
|
| Endoribonucleases | 2 | 2013 | 57 | 0.250 |
Why?
|
| Mass Screening | 3 | 2024 | 698 | 0.250 |
Why?
|
| Cohort Studies | 7 | 2017 | 2620 | 0.250 |
Why?
|
| Fruit | 2 | 2015 | 101 | 0.250 |
Why?
|
| HIV Infections | 1 | 2013 | 955 | 0.240 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 2757 | 0.240 |
Why?
|
| Puerto Rico | 3 | 2024 | 138 | 0.240 |
Why?
|
| Massachusetts | 4 | 2024 | 2145 | 0.230 |
Why?
|
| Health Services Research | 2 | 2017 | 265 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2025 | 464 | 0.220 |
Why?
|
| Biomarkers | 3 | 2022 | 1480 | 0.220 |
Why?
|
| Age Factors | 4 | 2021 | 1586 | 0.210 |
Why?
|
| Adolescent | 6 | 2024 | 6297 | 0.210 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2023 | 45 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2026 | 184 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 740 | 0.200 |
Why?
|
| Multiple Sclerosis | 1 | 2026 | 226 | 0.190 |
Why?
|
| Occult Blood | 1 | 2023 | 19 | 0.190 |
Why?
|
| Delivery of Health Care | 4 | 2026 | 431 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 191 | 0.190 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2022 | 14 | 0.190 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 47 | 0.180 |
Why?
|
| Survival Rate | 3 | 2025 | 844 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 38 | 0.180 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 2701 | 0.170 |
Why?
|
| Smoking | 3 | 2021 | 862 | 0.170 |
Why?
|
| Electronics | 1 | 2021 | 33 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 460 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 69 | 0.170 |
Why?
|
| Trans Fatty Acids | 1 | 2020 | 5 | 0.170 |
Why?
|
| Erythrocyte Membrane | 1 | 2020 | 25 | 0.160 |
Why?
|
| Multiple Chronic Conditions | 1 | 2021 | 39 | 0.160 |
Why?
|
| Outpatients | 1 | 2022 | 143 | 0.160 |
Why?
|
| Pandemics | 2 | 2022 | 674 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 66 | 0.160 |
Why?
|
| Precision Medicine | 2 | 2019 | 129 | 0.160 |
Why?
|
| Europe | 1 | 2021 | 199 | 0.160 |
Why?
|
| Kallikreins | 1 | 2020 | 9 | 0.160 |
Why?
|
| Social Class | 1 | 2021 | 137 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 134 | 0.160 |
Why?
|
| Antigens | 1 | 2021 | 145 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2021 | 73 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2012 | 576 | 0.160 |
Why?
|
| C-Reactive Protein | 3 | 2014 | 170 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2010 | 190 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 17 | 0.150 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 70 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2026 | 702 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 767 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2020 | 309 | 0.150 |
Why?
|
| Hospitals | 1 | 2022 | 387 | 0.140 |
Why?
|
| Human papillomavirus 16 | 1 | 2008 | 20 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 239 | 0.140 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2018 | 17 | 0.140 |
Why?
|
| Prognosis | 3 | 2019 | 1784 | 0.140 |
Why?
|
| Prevalence | 2 | 2026 | 1445 | 0.140 |
Why?
|
| Periodontal Diseases | 1 | 2008 | 17 | 0.140 |
Why?
|
| Periodontitis | 1 | 2008 | 15 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2023 | 496 | 0.140 |
Why?
|
| Incidence | 5 | 2025 | 1419 | 0.140 |
Why?
|
| Sex Factors | 1 | 2021 | 992 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 166 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 166 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2018 | 754 | 0.130 |
Why?
|
| Telemedicine | 1 | 2022 | 362 | 0.130 |
Why?
|
| Organizational Objectives | 1 | 2017 | 59 | 0.130 |
Why?
|
| Lymphoma | 1 | 2017 | 101 | 0.130 |
Why?
|
| Dairy Products | 1 | 2017 | 16 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2019 | 129 | 0.120 |
Why?
|
| Education | 1 | 2017 | 66 | 0.120 |
Why?
|
| Milk | 1 | 2017 | 47 | 0.120 |
Why?
|
| Medical Oncology | 1 | 2017 | 69 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1113 | 0.120 |
Why?
|
| Health Personnel | 2 | 2013 | 384 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 2018 | 166 | 0.120 |
Why?
|
| Cholesterol | 1 | 2017 | 261 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 261 | 0.120 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 528 | 0.120 |
Why?
|
| Inflammation | 2 | 2021 | 1192 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 19 | 0.120 |
Why?
|
| Genomics | 1 | 2018 | 384 | 0.110 |
Why?
|
| Connecticut | 1 | 2015 | 90 | 0.110 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 74 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2016 | 210 | 0.110 |
Why?
|
| Meat | 1 | 2015 | 38 | 0.110 |
Why?
|
| Vegetables | 1 | 2015 | 68 | 0.110 |
Why?
|
| Vasectomy | 1 | 2014 | 1 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 643 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 199 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2013 | 29 | 0.100 |
Why?
|
| Veterans | 1 | 2021 | 761 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 263 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1149 | 0.100 |
Why?
|
| Time Factors | 3 | 2012 | 3762 | 0.100 |
Why?
|
| Life Style | 1 | 2015 | 321 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 3 | 0.090 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.090 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 4 | 0.090 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2012 | 7 | 0.090 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 10 | 0.090 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 9 | 0.090 |
Why?
|
| Obesity | 1 | 2021 | 1274 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 120 | 0.090 |
Why?
|
| Receptors, Calcitriol | 1 | 2012 | 33 | 0.090 |
Why?
|
| Nursing Homes | 1 | 2018 | 686 | 0.090 |
Why?
|
| Seasons | 1 | 2012 | 139 | 0.090 |
Why?
|
| Health Behavior | 1 | 2015 | 484 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 249 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2015 | 897 | 0.090 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 350 | 0.080 |
Why?
|
| Genotype | 3 | 2013 | 673 | 0.070 |
Why?
|
| California | 2 | 2020 | 177 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2026 | 6872 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 794 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 730 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 37 | 0.060 |
Why?
|
| Cell Membrane | 2 | 2022 | 506 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2020 | 2102 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1574 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2013 | 324 | 0.060 |
Why?
|
| Demography | 1 | 2026 | 178 | 0.060 |
Why?
|
| Logistic Models | 2 | 2018 | 1269 | 0.060 |
Why?
|
| Vietnam | 1 | 2025 | 185 | 0.050 |
Why?
|
| Trust | 1 | 2024 | 79 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2024 | 141 | 0.050 |
Why?
|
| Patient Participation | 1 | 2024 | 234 | 0.050 |
Why?
|
| Life Tables | 1 | 2020 | 23 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 159 | 0.040 |
Why?
|
| Marital Status | 1 | 2020 | 44 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2010 | 5 | 0.040 |
Why?
|
| Finland | 1 | 2010 | 20 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2014 | 394 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 44 | 0.040 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 8 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2020 | 75 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 5 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 91 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 111 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5792 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 27 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 316 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 34 | 0.040 |
Why?
|
| Colorado | 1 | 2019 | 21 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 377 | 0.040 |
Why?
|
| Washington | 1 | 2019 | 24 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 497 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 94 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 372 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 371 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2020 | 199 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 527 | 0.030 |
Why?
|
| Self Report | 1 | 2020 | 390 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 159 | 0.030 |
Why?
|
| Research | 1 | 2019 | 194 | 0.030 |
Why?
|
| Data Collection | 1 | 2019 | 382 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2020 | 307 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 235 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 317 | 0.030 |
Why?
|
| Research Personnel | 1 | 2017 | 82 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Mentors | 1 | 2017 | 118 | 0.030 |
Why?
|
| Kenya | 1 | 2016 | 97 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 39 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 32 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 588 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 179 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 464 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 415 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 456 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 283 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 896 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 374 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 32 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 630 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2013 | 103 | 0.020 |
Why?
|
| Prostate | 1 | 2013 | 122 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 875 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 31 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 47 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1693 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4607 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 21345 | 0.010 |
Why?
|